Swiss team stops breast cancer metastasis by fooling cells into becoming fat

An African-American female technician positions a Caucasian woman at an imaging machine to receive a mammogram.
About 5% of breast cancer patients already have metastatic disease when they are diagnosed. (NCI)

What if doctors could stop breast cancer from spreading by turning tumor cells into something harmless, like fat? That question led scientists at the University of Basel to a combination of two FDA-approved drugs that, in mice, transformed breast cancer cells into fat cells—and prevented the tumors from growing and spreading.

The combo treatment consisted of GlaxoSmithKline’s diabetes drug Avandia (rosiglitazone) and Novartis’ cancer treatment Mekinist (trametinib). “As far as we can tell from long-term culture experiments, the cancer cells-turned-fat cells remain fat cells and do not revert back to breast cancer cells,” said Gerhard Christofori, a professor of biochemistry at the University of Basel, in a statement.

The key to the Swiss scientists’ experiment was their ability to exploit a developmental phase during which cancer cells are amenable to turning into many different types of cells. When cancer cells enter that stage, called epithelial-mesenchymal transition, they become more like stem cells, but they also promote metastasis.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

The researchers gave doses of Avandia and Mekinist to mice that had human breast cancer cells implanted into them. The drugs slowed the growth of the primary tumors and prevented the cancer from spreading. They published their findings in the journal Cancer Cell.

RELATED: Using CRISPR to turn cancer cells against themselves

Breast cancer is the second most common form of the disease after skin cancer, according to the American Society of Clinical Oncology, and about 5% of patients already have metastatic disease when they are diagnosed. Women with metastatic breast cancer have a five-year survival rate of just 27%.

Mekinist is currently approved in combination with Tafinlar to treat patients with BRAF-mutated melanoma or non-small cell lung cancer. Several studies of Mekinist in combination with a variety of other treatments in breast cancer are ongoing.

As for Avandia, it was once a $3-billion-a-year hit in diabetes, but controversies over potential cardiovascular risks drove sales down to $183 million in 2011, just before generic competitors entered the market. In 2015, the FDA said that after years of monitoring side effect reports on the drug, it was lifting all prescribing restrictions.

The University of Basel researchers believe the combination of Mekinist and Avandia forces enough cancer cells to differentiate into fat that the primary tumor is no longer able to resist conventional chemotherapy. Their next step is to try their fat-conversion approach along with chemotherapy, and to see if the combinations work in other cancers as well.

Said Christofori said in a release from the University of Basel, “This innovative therapeutic approach could be used in combination with conventional chemotherapy to suppress both primary tumor growth and the formation of deadly metastases."

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.